August 2, 2011—Health care providers enrolled in the 340B drug discount program will appeal in person next week to a National Council for Prescription Drug Programs (NCPDP) work group to change its standards so that pharmacy benefits managers (PBMs) and private payers cannot use them to lower reimbursement for 340B retail drugs. Groups representing hospitals, hemophilia … [Read more...]
Deficit Reduction Plan Cast Shadow Over Federal Health Programs
OPA's appropriation likely to be frozen or reduced.August 2, 2011—Federal Medicare reimbursement to health care providers, payments to state Medicaid programs, and spending to administer the 340B drug discount program could be significantly curtailed under a 10-year deficit reduction bill that President Obama signed into law today. The Senate voted 74-26 to approve the bill this morning after the House passed it 269-161 the … [Read more...]
House Bill Would Add Inpatient Drugs to 340B, Lift Orphan Drug Discount Ban
Companion measure is expected to be introduced in the Senate.July 28, 2011—Bipartisan legislation was introduced in the U.S. House late yesterday to expand 340B drug discounts to the inpatient setting and lift the restriction on rural and free-standing cancer hospitals' access to 340B pricing on orphan drugs. The 340B Improvement Act of 2011 (H.R. 2674), sponsored by Reps. Cathy McMorris Rodgers (R-Wash.), Bobby Rush (D-Ill.), Jo Ann … [Read more...]
340B Hospitals Say They Can Comply with Orphan Drug Exclusion Rule
Monitor will report soon on others stakeholders' comments on proposed regulation.Editors' note: The federal government has begun releasing public comments on an important proposed regulation to implement health care reform's limit on rural and free-standing cancer hospitals' access to 340B pricing on orphan drugs. This is the first in a series of articles on 340B stakeholders' reactions to the proposed rule. Check back with the Monitor in the coming days … [Read more...]
340B Patient Definition Guidance Is Back Under Review
Unclear if it will be published this year, Pedley says.July 19, 2011—The Health Resources and Services Administration's (HRSA) proposed redefinition of the term "patient" for purposes of 340B discounts is "still under review" and could remain so for quite some time, Office of Pharmacy Affairs Director Krista Pedley announced last week during the 340B Coalition annual conference in Washington. Noting that she is … [Read more...]
OIG: States Neglecting Medicaid Rebates on Non-340B Drugs
Says CMS should help them identify "carved out" claims on physician-administered drugs.July 8, 2011—The Centers for Medicare and Medicaid Services (CMS) should take action against states that are not collecting Medicaid rebates on physician-administered drugs bought outside of the 340B program, the U.S. Department of Health and Human Services Office of Inspector General (OIG) recommends in a new report. As a result, some hospitals may see greater activity by … [Read more...]
CMS Issues Medicare Hospital Outpatient Payment Proposal for 2012
Payment rate for separately payable drugs & biologicals set at ASP plus 4%.July 8, 2011—The Centers for Medicare and Medicaid Services (CMS) has proposed to budget $41.9 billion for Medicare reimbursement to hospital outpatient facilities in 2012, an increase of 1.5 percent above this year's level. At the same time, the payment rate for separately payable drugs and biologicals would decrease by 1 percent. In a proposed rule for the Hospital … [Read more...]